html5-img
1 / 10

MODULE 5 Take-Home Medication

Effective Risk Management Strategies in Outpatient Methadone Treatment: Clinical Guidelines and Liability Prevention Curriculum. MODULE 5 Take-Home Medication. Take-Home Medication . Medical Director responsibility Federal Regulation (42 CFR, Part 8 § 12( i )):

fauve
Download Presentation

MODULE 5 Take-Home Medication

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Effective Risk Management Strategies in Outpatient Methadone Treatment: Clinical Guidelines and Liability Prevention Curriculum MODULE 5 Take-Home Medication

  2. Take-Home Medication • Medical Director responsibility • Federal Regulation (42 CFR, Part 8 § 12(i)): • Absence of recent drug and alcohol abuse • Regular OTP attendance • Absence of behavioral problems at the OTP • Absence of recent criminal activity • Stable home environment and social relationships • Acceptable length of time in treatment • Assurance of safe storage • Rehabilitative benefits outweigh potential diversion risk Clinical Pharmacology, Chapter 5, (TIP) Treatment Improvement Protocol #43. http://www.ncbi.nlm.nih.gov/books/NBK25944/

  3. Federal Guideline Take-Home Medication: Restrictions Clinical Pharmacology, Chapter 5, (TIP) Treatment Improvement Protocol #43. http://www.ncbi.nlm.nih.gov/books/NBK25944/

  4. Take-Home Medication: Exceptions • OTP closed and holidays • Medical conditions • Rehabilitative potential • Emergency circumstances • State & Federal requirements • State approval/coordination • SAMHSA SMA-168 form • SAMHSA • “Dear Colleague” letters • Guidelines for Accreditation Clinical Pharmacology, Chapter 5, (TIP) Treatment Improvement Protocol #43. http://www.ncbi.nlm.nih.gov/books/NBK25944/

  5. Take-Home Medication: Monitoring • Review the rationale • Drug Testing • PDMP review • Review of all prescriptions • Attendance for counseling Clinical Pharmacology, Chapter 5, (TIP) Treatment Improvement Protocol #43. http://www.ncbi.nlm.nih.gov/books/NBK25944/

  6. Take-Home Medication: Legal Federal regulation permits THs for patients; however, it does not absolve the OTP of their legal responsibility.

  7. Take-Home Medication: Policies • The TIP 43 recommends the following diversion control policies: • Return empty bottles • Procedure for those who fail to return bottles • Stay open 7 days a week Clinical Pharmacology, Chapter 5, (TIP) Treatment Improvement Protocol #43. http://www.ncbi.nlm.nih.gov/books/NBK25944/

  8. Take-Home Medication: TOOLKIT • Conduct “call-backs” • Monitor take-home medication • Home safety inspections • Case management staff • Locked containers • Not a total guarantee for safety Clinical Pharmacology, Chapter 5, (TIP) Treatment Improvement Protocol #43. http://www.ncbi.nlm.nih.gov/books/NBK25944/

  9. Take-Home Medication: TOOLKIT • Screen for patients who: • Have children • Are using/abusing substances • Policies to address treatment interruptions: • Travel • Illnesses or disabilities • Bereavement / funerals • Emergencies • Hospitalizations Clinical Pharmacology, Chapter 5, (TIP) Treatment Improvement Protocol #43. http://www.ncbi.nlm.nih.gov/books/NBK25944/

  10. In Summary • Criteria for eligibility • State and federal criteria • Clinical judgment • Medical Director responsibility and accountability • Monitor, reassess and document

More Related